BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 15734959)

  • 1. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
    Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.
    Kraus I; Molden T; Holm R; Lie AK; Karlsen F; Kristensen GB; Skomedal H
    J Clin Microbiol; 2006 Apr; 44(4):1310-7. PubMed ID: 16597856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
    Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
    Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
    Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL
    Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.
    Varnai AD; Bollmann M; Bankfalvi A; Speich N; Schmitt C; Griefingholt H; Kovács K; Klozoris C; Bollmann R
    Oncol Rep; 2008 Feb; 19(2):457-65. PubMed ID: 18202795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
    Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
    J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus detection by PCR assay in a large series of high-grade squamous intraepithelial lesions with cytohistological correlation and follow-up.
    Lerma Puertas E; Otal Salaverri C; Ríos Martín JJ; Sánchez Gómez A; Jiménez Caraballo A; González-Cámpora R
    Acta Cytol; 2011; 55(5):426-32. PubMed ID: 21986169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
    Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
    J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
    Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
    Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia.
    Lie AK; Risberg B; Borge B; Sandstad B; Delabie J; Rimala R; Onsrud M; Thoresen S
    Gynecol Oncol; 2005 Jun; 97(3):908-15. PubMed ID: 15943992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.
    Tropé A; Jonassen CM; Sjøborg KD; Nygård M; Dahl FA; Alfsen GC; Lie AK
    Gynecol Oncol; 2011 Nov; 123(2):257-62. PubMed ID: 21839500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implication of high risk human papillomavirus E6 and E7 mRNA in patients with intraepithelial lesions of the cervix in relationship to age.
    Frega A; Lorenzon L; Giovagnoli MR; De Sanctis L; Fabiano V; Lukic A; Moscarini M; Torrisi MR; French D
    Int J Immunopathol Pharmacol; 2011; 24(2):461-70. PubMed ID: 21658320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.
    Thomsen LT; Dehlendorff C; Junge J; Waldstrøm M; Schledermann D; Frederiksen K; Kjaer SK
    Int J Cancer; 2016 Oct; 139(8):1839-50. PubMed ID: 27004595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.
    Juric D; Mahovlić V; Rajhvajn S; Ovanin-Rakić A; Skopljanac-Macina L; Barisić A; Projić IS; Babić D; Susa M; Corusić A; Oresković S
    Coll Antropol; 2010 Mar; 34(1):19-24. PubMed ID: 20432728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of features indicating progression in atypical squamous cells with undetermined significance: human papillomavirus typing and DNA ploidy analysis from liquid-based cytologic samples.
    Bollmann R; Méhes G; Torka R; Speich N; Schmitt C; Bollmann M
    Cancer; 2003 Apr; 99(2):113-7. PubMed ID: 12704691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.